Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

White, M. H.;Bowden, R. A.;Sandler, E. S.;Graham, M. L.;Noskin, G. A.;Wingard, J. R.;Goldman, M.;van Burik, J. A.;McCabe, A.;Miller, C. B.;Gurwith, M.;Carole, B.

Author address: 

White, MH, Mem Sloan Kettering Canc Ctr, Infect Dis Serv, 1275 York Ave, New York, NY 10021 USA


We conducted a prospective, randomized, double-blind study comparing amphotericin B colloidal dispersion (ABCD) with amphotericin B in the empirical treatment of fever and neutropenia. Patients with neutropenia and unresolved fever after greater than or equal to 3 days of empirical antibiotic therapy were stratified by age and concomitant use of cyclosporine or tacrolimus. Patients were then randomized to receive therapy with ABCD (4 mg/[kg.d]) or amphotericin B (0.8 mg/[kg.d]) for less than or equal to 14 days. A total of 213 patients were enrolled, of whom 196 were evaluable for efficacy, Fifty percent of ABCD-treated patients and 43.2% of amphotericin B-treated patients had a therapeutic response (P = .31). Renal dysfunction was less likely to develop and occurred later in ABCD recipients than in amphotericin B recipients (P

abstract No: 


Full conference title: 

38th Annual Meeting of the American-Society-of-Hematology
    • ASH 38th (1997)